A biotech startup built to scour the world — and especially China — for promising drug candidates has a new leader: Ying Huang, the former CEO of Legend Biotech.
K2 Therapeutics, founded in 2024 by the investment firm MPM BioImpact, doesn’t discover drugs itself; it in-licenses candidates from other companies, with a particular focus on China-based biotechs whose science has become globally competitive. Huang’s appointment was announced August 11, 2026. The company has raised $50 million in seed financing, backed by MPM BioImpact (chaired by Ansbert Gadicke).
What’s in the pipeline
K2 already holds eight programs spanning preclinical to clinical testing, including an antibody-drug conjugate targeting the 5T4 protein (from Adcoris) and a “double-barreled” T-cell engager, ATG-106 (from Antengene), plus an option on a third undisclosed candidate. It runs as a “hub-and-spoke” organization — separate subsidiaries house different drugs — a structure meant to speed deal-making and allow individual programs to be spun out or taken public.
Why Huang
Huang ran Legend for seven years and helped develop Carvykti, the CAR-T cancer therapy partnered with Johnson & Johnson that generated nearly $2 billion in sales last year — one of the first commercially successful China-to-U.S. drug launches. That experience is exactly the playbook K2 is betting on: finding strong assets abroad and shepherding them to global markets.